MarketPulse

tumor microenvironment

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Molecular Partners Ag

Molecular Partners' MP0317 Shows Promise in Nature Cancer, Sparks CD40 Agonist Competition

Molecular Partners published positive Phase 1 data for MP0317, a CD40 agonist, in Nature Cancer, demonstrating tumor microenvironment remodeling with favorable safety in advanced cancer patients.
MOLNPhase 1 clinical trialimmunotherapy
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Calidi Biotherapeutics Advances Tumor-Targeted BiTE Platform Toward Clinical Development

Calidi Biotherapeutics advances RedTail virotherapy platform combining BiTE and IL-15 therapies for solid tumors, aiming to overcome immunosuppressive microenvironments. IND submission planned for 2026.
CLDIsolid tumorsRedTail platform